Through the collaboration, BeiGene will be granted access to Nona Biosciences' proprietary fully human transgenic mice platform Harbour Mice
This expanded collaboration between Nona and BeiGene will extend to the Harbour Mice HCAb platform. (Credit: BeiGene, Inc.)
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from “Idea to IND”, announced an agreement with BeiGene, Ltd. to expand the companies’ discovery strategic collaboration leveraging Nona’s proprietary Harbour Mice platform.
Through the collaboration, BeiGene will be granted access to Nona Biosciences’ proprietary fully human transgenic mice platform Harbour Mice. Previously, in 2018, BeiGene obtained rights to use the proprietary Harbour Mice H2L2 platform for multiple antibody programs. This expanded collaboration between Nona and BeiGene will extend to the Harbour Mice HCAb (heavy chain only antibody format) platform to further improve therapeutic antibody discovery efficiency and flexibility.
“We are delighted to broaden our collaboration with BeiGene on antibody discovery. Our platform has enabled biotechnology and pharmaceutical companies as well as academia to accelerate innovative drug discovery for more than a decade. BeiGene has been a long-term partner for us, and partnership expansion is emblematic of Nona’s accumulated knowledge and expertise in drug discovery,” said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences.
Source: Company Press Release